LILoredana Nicoleta Ionică

Loredana Nicoleta Ionică

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Loredana Nicoleta Ionică has a total of 32 co-authors. Here are the top co-authors by number of shared publications:

  • Adrian Sturza

    Department III—Pathophysiology, “Victor Babeș” University of Medicine and Pharmacy of Timișoara, E. Murgu Sq. No. 2, 300041 Timișoara, Romania

    5 shared publications
  • Danina Mirela Muntean

    Centre for Molecular Research in Nephrology and Vascular Disease, Faculty of Medicine, “Victor Babes” University of Medicine and Pharmacy, No. 2, Eftimie Murgu Sq., 300041 Timisoara, Romania

    4 shared publications
  • Lucian Petrescu

    Cardiology Department, “Victor Babes” University of Medicine and Pharmacy, 2 Eftimie Murgu Sq., 300041 Timisoara, Romania

    3 shared publications
  • Maria-Daniela Dănilă

    Department III Functional Sciences—Pathophysiology, “Victor Babeș” University of Medicine and Pharmacy of Timișoara, E. Murgu Sq. No. 2, 300041 Timișoara, Romania

    3 shared publications
  • Raluca Șoșdean

    Cardiology Department, “Victor Babes” University of Medicine and Pharmacy, 2 Eftimie Murgu Square, 300041 Timisoara, Romania

    3 shared publications
  • Adina Ionac

    Department VI—Cardiology, “Victor Babeș” University of Medicine and Pharmacy of Timișoara, E. Murgu Sq. No. 2, 300041 Timișoara, Romania

    2 shared publications

Latest Publications

  • Open Access

    Hyperuricemia Reflects Cardiometabolic Burden Rather than Left Ventricular Systolic Dysfunction Across Heart Failure Phenotypes: Insights from a Real-World Acute Heart Failure Cohort

    by Raluca Ibănescu, Sebastian Ciurescu, Roxana Buzaș, Anda Gabriela Militaru, Diana-Alexandra Mîțu, Loredana Nicoleta Ionică, Iacob-Daniel Goje, Ciprian Rachieru, Paul-Gabriel Ciubotaru, Vlad Sabin Ivan, et al.

    Background/Objectives: Acute heart failure (AHF) is a leading cause of global morbidity, necessitating the search for reliable biomarkers to guide risk stratification. While hyperuricemia is highly prevalent in heart failure patients and historically considered a potential “cardiotoxin”, contemporary evidence suggests that it may function as a surrogate biomarker for cardiometabolic distress rather than an independent driver of myocardial dysfunction. This study aimed to determine whether serum uric acid acts as an independent predictor of left ventricular ejection fraction (LVEF) in a high-risk cardiometabolic cohort. Methods: This retrospective, cross-sectional study analyzed 306 patients hospitalized for acute heart failure at a tertiary hospital in Timisoara, Romania. Data were analyzed using JASP (v0.96). Statistical methods included Shapiro–Wilk testing, Spearman’s rank-order correlation, and independent samples t-tests. Multivariable ordinary least squares linear regression and maximum likelihood logistic regression were employed to identify predictors of LVEF and diagnostic classification, adjusting for comorbidities and diuretic administration. Results: Hyperuricemia was present in 64.6% of the cohort. Multivariable linear regression demonstrated that while age, sex, and diuretic use significantly predicted LVEF variance, serum uric acid did not (p = 0.356). Furthermore, logistic regression confirmed uric acid possessed no diagnostic utility in differentiating heart failure phenotypes (OR = 0.995; p = 0.973). Conclusions: Serum uric acid is not an independent predictor of reduced ejection fraction in acute heart failure patients. Elevated uric acid appears to be a biochemical shadow of generalized metabolic distress, systemic congestion, and the pharmacokinetic effects of diuretic therapy rather than a pathological driver of contractile dysfunction.

  • Cardiac Dysfunction and Heart Failure Caused by Cancer Therapy-Induced Cardiotoxicity

    by Raluca ȘoșDean, Silvia Giuchici, Loredana N. Ionică, Adina V. Furdui-Lința, Adrian Sturza, Danina M. Muntean, Daniel F. Lighezan, Roberto Bolli

  • Open Access

    Monoamine Oxidase Contributes to Valvular Oxidative Stress: A Prospective Observational Pilot Study in Patients with Severe Mitral Regurgitation

    by Raluca Șoșdean, Maria D. Dănilă, Loredana N. Ionică, Alexandru S. Pescariu, Monica Mircea, Adina Ionac, Cristian Mornoș, Constantin T. Luca, Horea B. Feier, Danina M. Muntean, et al.

    Monoamine oxidases (MAOs), mitochondrial enzymes that constantly produce hydrogen peroxide (H2O2) as a byproduct of their activity, have been recently acknowledged as contributors to oxidative stress in cardiometabolic pathologies. The present study aimed to assess whether MAOs are mediators of valvular oxidative stress and interact in vitro with angiotensin 2 (ANG2) to mimic the activation of the renin–angiotensin system. To this aim, valvular tissue samples were harvested from 30 patients diagnosed with severe primary mitral regurgitation and indication for surgical repair. Their reactive oxygen species (ROS) levels were assessed by means of a ferrous oxidation xylenol orange (FOX) assay, while MAO expression was assessed by immune fluorescence (protein) and qRT-PCR (mRNA). The experiments were performed using native valvular tissue acutely incubated or not with angiotensin 2 (ANG2), MAO inhibitors (MAOI) and the angiotensin receptor blocker, irbesartan (Irb). Correlations between oxidative stress and echocardiographic parameters were also analyzed. Ex vivo incubation with ANG2 increased MAO-A and -B expression and ROS generation. The level of valvular oxidative stress was negatively correlated with the left ventricular ejection fraction. MAOI and Irb reduced valvular H2O2. production. In conclusion, both MAO isoforms are expressed in pathological human mitral valves and contribute to local oxidative stress and ventricular functional impairment and can be modulated by the local renin–angiotensin system.


  • Open Access

    The Off-Target Cardioprotective Mechanisms of Sodium–Glucose Cotransporter 2 Inhibitors: An Overview

    by Loredana N. Ionică, Adina V. Lința, Alina D. Bătrîn, Iasmina M. Hâncu, Bogdan M. Lolescu, Maria D. Dănilă, Lucian Petrescu, Ioana M. Mozoș, Adrian Sturza, Danina M. Muntean

    Sodium–glucose cotransporter 2 inhibitors (SGLT2i), a novel class of glucose-lowering drugs, have revolutionized the management of heart failure with reduced and preserved ejection fraction, regardless of the presence of diabetes, and are currently incorporated in the heart failure guidelines. While these drugs have consistently demonstrated their ability to decrease heart failure hospitalizations in several landmark clinical trials, their cardioprotective effects are far from having been completely elucidated. In the past decade, a growing body of experimental research has sought to address the molecular and cellular mechanisms of SGLT2i in order to provide a better understanding of the off-target acute and chronic cardiac benefits, beyond the on-target renal effect responsible for blood glucose reduction. The present narrative review addresses the direct cardioprotective effects of SGLT2i, delving into the off-target mechanisms of the drugs currently approved for heart failure therapy, and provides insights into future perspectives.


  • Open Access

    Monoamine Oxidase (MAO) Is Expressed at the Level of Mitral Valve with Severe Regurgitation in Hypertrophic Obstructive Cardiomyopathy: A Case Report

    by Ana Lascu, Raluca Șoșdean, Loredana Nicoleta Ionică, Alexandru S. Pescariu, Lucian Petrescu, Adina Ionac, Constantin T. Luca, Adrian Sturza, Horea B. Feier

    Hypertrophic obstructive cardiomyopathy (HOCM) is one of the most common hereditary heart diseases. The severely hypertrophied interventricular septum combined with the systolic anterior movement (SAM) of the mitral valve (MV) frequently cause a significant pressure gradient in the left ventricular outflow tract associated with varying degrees of mitral regurgitation (MR). We present the case of a 64-year-old female patient who was diagnosed with HOCM two years ago and was admitted to the Institute of Cardiovascular Disease with exertion dyspnea and fatigue. Transthoracic echocardiography revealed concentric, asymmetrical left ventricular hypertrophy, an elongated anterior mitral leaflet (AML) and a significant SAM causing severe regurgitation, with indication for valvular replacement Monoamine oxidase (MAO), a mitochondrial enzyme, with 2 isoforms, MAO-A and B, has emerged as an important source of reactive oxygen species (ROS) in the cardiovascular system, but literature data on its expression in valvular tissue is scarce. Therefore, we assessed MAO-A and B gene (qPCR) and protein (immune fluorescence) expression as well as ROS production (spectrophotometry and confocal microscopy) and in the explanted MV harvested during replacement surgery. MAO expression and ROS production (assessed by both methods) were further augmented following ex vivo incubation with angiotensin II, an effect that was reversed in the presence of either MAO-A (clorgyline) or B (selegiline) inhibitor, respectively. In conclusion, MAO isoforms are expressed at the level of severely impaired mitral valve in the setting of HOCM and can be induced in conditions that mimic the activation of renin-angiotensin-aldosterone system. The observation that the enzyme can be modulated by MAO inhibitors warrants further investigation in a patient cohort.


  • Open Access

    Metformin Acutely Mitigates Oxidative Stress in Human Atrial Tissue: A Pilot Study in Overweight Non-Diabetic Cardiac Patients

    by Ana Lascu, Loredana-Nicoleta Ionică, Adrian-Petru Merce, Maria-Daniela Dănilă, Lucian Petrescu, Adrian Sturza, Danina-Mirela Muntean, Caius Glad Streian

    Metformin, the first-line drug in type 2 diabetes mellitus, elicits cardiovascular protection also in obese patients via pleiotropic effects, among which the anti-oxidant is one of the most investigated. The aim of the present study was to assess whether metformin can acutely mitigate oxidative stress in atrial tissue harvested from overweight non-diabetic patients. Right atrial appendage samples were harvested during open-heart surgery and used for the evaluation of reactive oxygen species (ROS) production by means of confocal microscopy (superoxide anion) and spectrophotometry (hydrogen peroxide). Experiments were performed after acute incubation with metformin (10 µM) in the presence vs. absence of angiotensin II (AII, 100 nM), lipopolysaccharide (LPS, 1 μg/mL), and high glucose (Gluc, 400 mg/dL). Stimulation with AII, LPS, and high Gluc increased ROS production. The magnitude of oxidative stress correlated with several echocardiographic parameters. Metformin applied in the lowest therapeutic concentration (10 µM) was able to decrease ROS generation in stimulated but also non-stimulated atrial samples. In conclusion, in a pilot group of overweight non-diabetic cardiac patients, acute incubation with metformin at a clinically relevant dose alleviated oxidative stress both in basal conditions and conditions that mimicked the activation of the renin–angiotensin–aldosterone system, acute inflammation, and uncontrolled hyperglycemia.